Triple-agonist metabolic peptide · LY3437943 · Eli Lilly
One peptide.
Three receptors.
Three metabolic outcomes.
Retatrutide is a once-weekly investigational triple agonist at the GIP, GLP-1, and glucagon receptors. Every trial number below is a downstream consequence of that receptor triad. Pick a dose to index the evidence.
The dose control is a data filter for interpretation only. Doses shown are trial-administered means — this is not dosing, administration, or medical guidance.
Executive conclusion
A high-efficacy metabolic polyagonist, with important unresolved outcomes questions
The current peer-reviewed evidence reports large mean weight reduction, HbA1c lowering, and MRI-measured liver-fat reduction in defined trial populations. Those findings are not head-to-head superiority results, and the evidence does not yet establish hard cardiovascular, renal, mortality, or histologic MASH outcomes.
Not simply another GLP-1 signal
Retatrutide combines GLP-1 and GIP incretin biology with glucagon-receptor activity. The most coherent interpretation is that appetite, glycemic, energy-expenditure, and hepatic-lipid mechanisms are acting together, with the liver-fat signal especially consistent with glucagon-receptor biology.
Strong intermediate outcomes, pending hard outcomes
Weight, HbA1c, MRI-PDFF liver fat, and DXA fat mass are meaningful research endpoints, but they remain distinct from myocardial infarction, stroke, kidney failure, liver decompensation, mortality, and biopsy-proven fibrosis outcomes.
The mechanism
Three receptors, one engineered balance
Retatrutide is a deliberately biased polyagonist — more potent than endogenous GIP at the GIP receptor, and less potent than the native ligands at the glucagon and GLP-1 receptors. The three levers below combine appetite and glycemic control with glucagon-driven energy expenditure and hepatic lipid effects.
- Appetite reduction and delayed gastric emptying
- Glucose-dependent insulin secretion
- Glucagon suppression
- Drives weight loss and HbA1c reduction
- Incretin activity and insulin secretion
- Possible adipose-tissue and tolerability interactions
- Synergy with GLP-1 biology
- Engineered more potent than endogenous GIP
- Increased energy expenditure
- Hepatic lipid oxidation
- Plausible driver of the large liver-fat effect
- Balanced by incretin agonism to avoid raising glucose
Human proof of concept
The phase 1b study established weekly exposure and translational plausibility
The 2022 Lancet multiple-ascending-dose trial was not an outcomes trial. Its importance is that the triple-agonist concept produced human glucose and weight effects at weekly exposures, with pharmacokinetics consistent with later once-weekly programs.
It made the larger phase 2 program scientifically defensible
The phase 1b trial linked receptor design to human metabolic activity: plasma glucose fell, HbA1c fell, and the highest escalation group showed meaningful body-weight reduction over 12 weeks. That made the later obesity, type 2 diabetes, and liver-fat programs biologically coherent rather than isolated findings.
GI events appeared early as the dominant class-consistent issue
Treatment-emergent adverse events occurred in 63% of LY3437943-treated participants, 60% of dulaglutide-treated participants, and 54% of placebo participants. Gastrointestinal events were the most common adverse events, foreshadowing the dose- and titration-related safety pattern seen later.
Outcome · weight
Unusually large body-weight reduction
In the published NEJM phase 2 dose-ranging obesity trial (adults without diabetes), mean weight loss deepened with dose and continued from week 24 to week 48. This is a phase 2 signal—not a personalized forecast or definitive phase 3 outcomes result.
Weight-loss dose-response
Mean % body-weight change · week 24 → week 48
Responder rates at week 48
% of participants reaching each weight-loss threshold
Efficacy-estimand responder reference using multiple imputation; maintenance-dose groups are pooled and are not re-indexed by the dose control.
Outcome · glucose
Robust glycemic control across phases
HbA1c reductions are consistent from the phase 2 type-2-diabetes trial through the peer-reviewed TRANSCEND-T2D-1 phase 3 anchor. No severe hypoglycemia was reported in either — consistent with glucose-dependent incretin biology.
HbA1c change — phase 2 vs phase 3
LS-mean change · phase 2 wk 24 (NCT04867785) & phase 3 wk 40 (TRANSCEND)
Body-weight change in type 2 diabetes
phase 2 wk 36 & phase 3 wk 40 — weight loss is real but smaller than in non-diabetes cohorts
Outcome · liver
Profound MRI-measured liver-fat reduction
The Nature Medicine MASLD substudy is one of retatrutide's strongest non-weight signals — consistent with the glucagon-receptor hypothesis. Important limit: MRI liver fat is a surrogate, not biopsy-proven MASH resolution or fibrosis regression.
Relative liver-fat change
MRI-derived · week 24 · by dose
Liver-fat normalization
% reaching <5% liver fat · week 24
Total fat-mass reduction (DXA)
phase 2 T2D substudy · week 36
Fat mass shown; lean-mass loss proportion was broadly comparable with other obesity therapies.
Safety and tolerability
The dominant published safety pattern is gastrointestinal, but the unresolved questions are broader
Across published human trials, the most consistent adverse-event pattern is dose-related gastrointestinal intolerance, usually mild to moderate and attenuated by lower starting dose or slower escalation. Longer and larger trials remain necessary for rare events and hard outcomes.
Gastrointestinal adverse-event rates
Phase 2 T2D · dominant tolerability finding · descriptive observed rates
Descriptive observed adverse-event rates only. Not dosing or titration guidance. Lower starting dose and slower escalation reduced GI intolerance.
Signals that should be visible on the public research page
- NEJM obesity phase 2 reported dose-dependent heart-rate increases that peaked around week 24 and then declined.
- No severe hypoglycemia was reported in the published T2D phase 2 trial or TRANSCEND-T2D-1.
- TRANSCEND-T2D-1 reported adverse-event discontinuations of 2% to 5% in retatrutide groups and 0% for placebo.
- TRANSCEND-T2D-1 reported two deaths in the 4 mg group, both judged unrelated to study drug.
Class-relevant monitoring
Gallbladder disease, pancreatitis surveillance, delayed gastric emptying interactions, and dehydration risk remain important longer-term questions.
Body-composition risk
DXA data support substantial fat-mass reduction, but absolute lean-mass loss, nutrition, and sarcopenia risk still matter at high total weight loss.
Special populations
Pregnancy, lactation, adolescents, frail older adults, severe gastrointestinal disease, and advanced organ impairment require dedicated evidence.
Weight of evidence
What is proven vs what is disclosed
The largest obesity numbers now circulating come from company- and conference-disclosed phase 3 studies that are not yet peer-reviewed. They are kept physically separate from the published data above and are never co-plotted with it.
Published, PMID-cited
Conference / company-disclosed
Treat as preliminary until full methods and peer-reviewed tables publish. Cite only as "reported/presented, pending peer review."
Methodologic limitations
What the evidence does not yet prove
The page should be visually strong, but scientifically conservative. Retatrutide's published efficacy signals are large; the unanswered questions are durability, comparative superiority, patient selection, and hard cardiometabolic, renal, and liver outcomes.
Mostly 12 to 48 weeks, plus 40-week phase 3 T2D
Obesity and metabolic disease are chronic. Durability after discontinuation and multi-year safety remain outside the strongest published evidence base.
Surrogates are useful, not definitive
Weight, HbA1c, MRI liver fat, and DXA body composition are important but do not prove MACE reduction, kidney protection, mortality benefit, or biopsy-confirmed MASH/fibrosis outcomes.
Generalizability is not automatic
Published studies used defined BMI, HbA1c, background-therapy, and exclusion criteria. Advanced disease, high-risk, or medically complex populations need direct evidence.
Do not overstate superiority to semaglutide or tirzepatide
Published retatrutide trials show very large effects, but cross-trial comparisons are confounded by trial duration, population, baseline BMI, diabetes status, titration, adherence, estimands, and missing-data rules. TRIUMPH-5 is the key head-to-head trial designed to compare retatrutide with tirzepatide.
Research facts, not treatment claims
Use source-attributed language such as "in a phase 2 NEJM trial, retatrutide 12 mg was associated with 24.2% mean weight reduction at 48 weeks." Avoid claims that any product treats obesity, diabetes, MASLD, MASH, knee osteoarthritis, sleep apnea, cardiovascular disease, or kidney disease.
Development arc
From discovery to phase 3, 2022–2026
Evidence landscape
The clinical-trial program
Major records from ClinicalTrials.gov. Outcomes trials (TRIUMPH-Outcomes, SYNERGY-Outcomes) will test the hard cardiometabolic, renal, and liver questions the surrogate endpoints above cannot answer.
| NCT | Program | Status | Population | Enrollment | Primary focus |
|---|